Regulation of bFGF gene expression and subcellular distribution of bFGF protein in adrenal medullary cells by unknown
Regulation of bFGF Gene Expression and Subcellular 
Distribution of bFGF Protein in Adrenal Medullary Cells 
Michal K. Stachowiak,* John Moffett,* Anna Joy,* Elzbieta Puchacz,* Robert Florkiewicz,§ 
and Ewa K. Stachowiak* 
Barrow Neurological Institute, *  Laboratory of Molecular Neurobiology, *  Laboratory of Neuro-oncology, Phoenix, Arizona 85013; 
and The Whittier Institute, La Jolla, California 92037 
Abstract.  Basic fibroblast growth factor (bFGF), a 
potent mitogenic/neurotrophic  factor, controls the de- 
velopment and plasticity of many types of neural cells. 
In adrenal chromaflin cells, the appearance of bFGF 
protein coincided with the establishment of functional 
innervation,  suggesting induction by trans-synaptic sig- 
nals.  In cultured bovine adrenal medullary cells West- 
ern blot analysis revealed 18-, 23-, and 24-kD bFGF 
isoforms in the cytosolic and nuclear fractions.  Stimu- 
lation of acetylcholine nicotinic receptors or hormonal 
angiotensin II receptors or the direct stimulation of 
adenylate cyclase with forskolin or protein kinase C 
(PKC) with PMA increased the content of all bFGF 
isoforms. Increases in the levels of intracellular bFGF 
did not result in detectable presence of bFGF proteins 
in culture medium.  Instead, bFGF proteins accumu- 
lated in the cytoplasm or the nucleus depending on 
whether PKC or cAMP pathways were activated. 
The long-term nuclear forskolin-induced accumula- 
tion of bFGF was prevented by cycloheximide or by 
antisense bFGF oligonucleotide and was also accom- 
panied by an increase in bFGF mRNA. We used lu- 
ciferase reporter plasmids containing the human bFGF 
promoter to show that the induction of bFGF resulted 
from transcriptional  activation of the bFGF gene and 
was mediated by regulatory sequences located up- 
stream from its transcription  start site.  Stimulation of 
bFGF gene expression by forskolin and PMA was syn- 
ergistic and was mediated through different promoter 
regions.  The results suggest that stimulation by cAMP 
and PKC is mediated through novel cis elements.  The 
regulation of bFGF protein content also involves post- 
transcriptional  mechanisms since changes in the levels 
of individual bFGF isoforms were different depending 
on whether cells were treated with carbachol or an- 
giotensin II, forskolin,  or PMA. 
The present study indicates that bFGF is an intra- 
crine cytoplasmic-nuclear factor, whose expression is 
regulated by trans-synaptic and hormonal  stimuli and 
which may act as a direct mediator of genomic re- 
sponses to afferent stimulation. 
ENESIS of cells in  the developing  nervous  system, 
their differentiation,  and survival are controlled by a 
variety of protein growth factors (Yamamori,  1992). 
One such protein is basic fibroblast growth factor (bFGF)  ~, 
a member of the family  of heparin binding  growth/neuro- 
trophic factors (Wagner, 1991). bFGF is expressed in de- 
veloping  nervous tissue (Ernfors  et al.,  1990;  Grothe and 
Unsicker,  1990; Grothe et al.,  1991). It stimulates  mitosis 
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of neuroblasts (Gensburger et al., 1987; Mayer et al., 1993), 
affects their differentiation  (Stemple et al., 1988; Vescovi et 
al., 1993), ontogenic death (Dreyer et al., 1989), and stimu- 
lates neurite outgrowth  (Hatten et al.,  1988; Gurney et al., 
1992) and synapse formation  (Peng et al., 1991). bFGF also 
affects  mitosis and differentiation  of glial  precursor  ceils 
(Engele and Bohn, 1992; Vescovi et al., 1993) and stimulates 
proliferation  of vascular endothelial and smooth muscle cells 
(Hayek et al.,  1987). 
In some regions of the nervous system bFGF is expressed 
during  adulthood (Woodward  et al.,  1992;  Grothe et al., 
1991). Functions  of bFGF in the mature nervous tissue are 
still contested, bFGF may participate  in the response of ner- 
vous tissue to injury; it stimulates reactive transformation  of 
astrocytes (Kniss and Burry,  1988) and enhances regenera- 
tion of the damaged neuronal  pathways (Otto and Unsicker, 
1990).  bFGF may also act as a neuroprotective agent,  in- 
creasing survival of neurons during  trans-synaptic  stimula- 
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of the nervous tissue leads to structural reorganization simi- 
lar to that occurring during development, i.e., proliferation 
of  glial and neural cells, expansion of neuritic arbors, forma- 
tion of new synapses and angiogenesis (for review see Bailey 
and Kandell, 1993). These changes could reflect a mobiliza- 
tion of intrinsic growth factors like bFGE 
In contrast to numerous studies describing the pleiotropic 
effects of bFGF in the nervous system, little is known about 
the mechanisms that regulate bFGF synthesis, its restricted 
cellular expression, and how it exerts biological functions. 
Increases in the levels of bFGF mRNA have been observed 
in the adult brain tissue following denervation (Leonard et 
al.,  1993)  or epileptic  seizures  (Riva et al.,  1992).  This 
finding suggests that changes in neural activity could affect 
the expression of the bFGF gene. Factors that trigger these 
changes, their underlying mechanisms and functional sig- 
nificance remain unknown. The elucidation of the regulation 
of bFGF and bFGF receptor synthesis, represents an impor- 
tant step on the way to a comprehensive understanding of  the 
physiological roles of bFGE 
The  comparison of the  gene and protein  structures  of 
bFGF to other neurotrophic growth factors suggests that the 
mechanisms controlling both their synthesis and their action 
are  fundamentally different.  Unlike brain-derived neuro- 
trophic factor gene (Maisonpierre et al., 1991), bFGF gene 
does not contain CAAT or TATA box motives (Abraham et 
al., 1986a; Shibata et al., 1991). Little is known about mech- 
anisms through which transcription initiates at TATAA box- 
deficient promoters and how activity of these promoters is 
regulated (see discussion in Ackerman et al.,  1993).  Tran- 
scription of the bFGF gene leads to a variety (10 to 1.6 kb) 
of messenger  RNAs  that  differ  in  the  length  of the  3'- 
translated region (Abraham et al., 1986a; Prats et al., 1989; 
Florkiewicz and Sommer, 1989; Zuniga et al., 1993). Trans- 
lation of bFGF mRNA initiates from an ATG codon yielding 
an  18-kD  protein and from three CTG codons producing 
higher molecular weight bFGF isoforms (Florkiewicz and 
Sommer, 1989; Powell and Klagsbrun, 1991). The structural 
characterization of  bFGF proteins has raised many questions 
regarding their possible mechanisms of action, bFGF lacks 
a signal sequence found in other secreted proteins (Abraham 
et al., 1986a,b) and is also absent in Golgi, arguing against 
its incorporation into secretory granules or secretory vesi- 
cles (Matsuda et al.,  1992;  Mignatti et al.,  1992).  Unlike 
NGF, or brain-derived neurotrophic factor and many other 
neurotrophic  factors,  bFGF  is  primarily  found  cell  as- 
sociated. Only the shortest AUG-initiated 18-kD bFGF iso- 
form may associate with the cell membrane (Florkiewicz et 
al.,  1991). Very little or no bFGF is found in the medium 
of most cultured cells (Schweigerer et al., 1987; Vlodawski 
et al., 1987; Moscatelli, 1988), and only a small fraction of 
total bFGF is bound to cell surface heparan sulfate pro- 
teoglycans (Baghkin  et al.,  1992).  Nevertheless, the pres- 
ence of plasma membrane receptors for bFGE and studies 
with neutralizing bFGF antibodies have indicated that bFGF 
may act extracellularly (Sato and Rifldn, 1988). It is possible 
that leakage from lysed or damaged cells is the primary 
source of extracellular bFGF (Schechter,  1992). 
A convenient model to study mechanisms that control the 
expression and function of bFGF in neural cells is chro- 
marlin  cells  of the  adrenal  medulla.  Adrenal  medullary 
pheochromocytes, like the noradrenergic neurons in sym- 
pathetic ganglia, are derived from the neural crest (Landis 
and Patterson, 1981). Their development and functions are 
regulated by trans-synaptic as well as hormonal signals. The 
mitotic activity of adrenal medullary cells declines during 
the development of the adrenal medulla. Nevertheless, the 
volume and number of cells of the adrenal medulla increase 
throughout life (Coupland,  1991). Even the adult adrenal 
medulla may undergo hyperplasia, increased vascularization 
and, in some instances, neoplastic transformation (Tischler 
and DeLeUis,  1988; Tischler et al., 1988). Stimuli that trig- 
ger these changes increase the activity of  the nerves innervat- 
ing the adrenal medulla or directly stimulate acetylcholine 
receptors on adrenal medullary cells (Malvaldi and Viola- 
Magni,  1972;  for review see Tischler and DeLellis, 1988; 
Tischler et al.,  1988). 
In the rat adrenal medulla,  the presence  of bFGF im- 
munoreactivity is detected for the first time at day 8 of post- 
natal life (Grothe and Unsicker,  1990).  The initial appear- 
ance of bFGF and subsequent increase  in  its  expression 
coincide with the establishment of functional innervation of 
chromaffin cells suggesting that they are induced by trans- 
synaptic signals. This apparent regulation of bFGF expres- 
sion by splanchnic nerve terminals suggests that bFGF could 
serve as an intermediary in the neural regulation of adrenal 
medullary cells. Indeed, bFGF stimulates the proliferation 
of  cultured chromaffin cells from neonatal and adult rat adre- 
nal medullae (Stempele et al.,  1990;  Frodin and Gammel- 
toft, 1994; Tischler et al., 1993). Unlike NGF, bFGF stimu- 
lates proliferation of adrenal medullary cells in the presence 
of glucocorticoids (Stemple et al., 1988) and therefore could 
mediate hyperplasia and vascularization of the adult adrenal 
medulla,  bFGF also  induces phosphorylation of tyrosine 
hydroxylase (TH)  protein  (Rydel and Greene,  1987)  and 
stimulates expression of the TH and pEK genes (Puchacz et 
al.,  1993).  Through these effects bFGF could increase the 
synthesis and release of catecholamines and enkephalins. 
To determine if bFGF may mediate afferent stimulation- 
induced adaptations in the adrenal medulla, we examined 
whether trans-synaptic or hormonal stimulation of the adre- 
nal medullary cells affects the production and bioavailability 
of bFGE As an experimental model, we have used primary 
cultures of adrenal chromaffin cells which allow the investi- 
gation of cellular responses to specific signals in a defined 
environment. Cultured chromaffin cells express bFGF (Blott- 
her et al., 1989; Puchacz et al., 1993) and retain many func- 
tional characteristics of chromaffin cells in vivo (Livett et 
al.,  1983;  for review see Stachowiak and Goc, 1992).  The 
synthesis and release of catecholamines, enkephalins and 
other hormones in cultured adrenal medullary cells are regu- 
lated by neurotransmitters and hormones similarly as in the 
adrenal gland. Signal transduction pathways (second mes- 
sengers, protein kinases, and nuclear transcriptional factors) 
that mediate those effects have been characterized (for review 
see Stachowiak and Goc,  1992;  Stachowiak et al.,  1994; 
Goc and Stachowiak, 1994).  Using this model we demon- 
strate that the stimulation of defined neurotransmitter and 
hormonal receptors and their known second messenger sys- 
tems increases the expression of the bFGF gene and the syn- 
thesis of bFGF protein and affects its subcellular distribu- 
tion.  Our  results  suggest  that  bFGF  acts  as  a  nuclear 
mediator of genomic responses to afferent cell stimulation. 
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Materials 
Recombinant bovine bFGF (18 kD) was purchased from Boehringer Mann- 
helm Biochemicals (Indianapolis, IN)  and the culture media were from 
Sigma Chem. Co. (St. Louis, MO). The remaining reagents were obtained 
from Boehringer Mannheim Biochemicals, Sigma Chem. Co., and Du Font 
NEN (Boston, MA). 
Cell Cultures 
Chromaffin cells from bovine adrenal medullae (BAMC) were prepared by 
collagenase digestion (Stachowiak et al.,  1990b)  and purified by density 
gradient centrifugation in Renografin as described in (Puchacz et al., 1993). 
For RNA and protein analysis, cells were plated in 30-mm wells at a density 
of 4  x  106 cells/well. Initially,  cultures were maintained in Dulbecco's 
modified Eagles's/F-12 medium containing 10% fetal calf serum, and then 
changed to serum-free medium supplemented with fatty acid-free bovine 
serum albumin (0.1 mg/ml) 2 d after plating. At that time many cells became 
flattened some with neurite-like processes. Drug treatments were initiated 
after cells were in serum-free medium for 24 h. Forskolin and phorbol esters 
(PMA or 4 alpha phorbol didecanoate) were added with 0.007%  DMSO as 
vehicle. DMSO had no effect on the expression of bFGF in BAMC. 
Isolation of  RNA and Northern Analysis of TH and 
bFGF mRNA 
Total  RNA was isolated from individual culture dishes by guanidinium 
isothiocyanate/cesium chloride  gradient  procedure  (Stachowiak  et  al., 
1990b).  The concentration of total RNA was estimated spectrophotometri- 
cally (A260nm). RNA was fractionated by electrophoresis on 1% agarose/ 
5 % formaldehyde  gels. Ethidium bromide-stained gels were photographed, 
and the 18S rRNA bands were scanned to estimate the amounts of RNA 
in individual lanes as previously described (Stachowiak et ai., 1990d;  Goc 
et al., 1992).  RNA was transferred to nitrocellulose or Nytran membranes 
(Schleicher &  Schuell, Keene, NH) and hybridized to 32p-labeled  bovine 
bFGF (Abraham et al., 1986b) or tyrosine hydroxylase eDNA (D'Mello et 
al.,  1989).  To ascertain that individual lanes contained a similar amount 
of total RNA and that RNA was completely transferred to the membrane, 
we compared the amounts of ethidium bromide-stained ribosomal RNA on 
gel before transfer and on gel and membrane after transfer. 
Western Analysis of  b  FG  F 
Cultured BAMC (2.5  x  107) were gently detached with a rubber police- 
man, washed twice with PBS by spinning in microcentrifuge at 3,000 rpm, 
and were then lysed. Alternatively, cells were washed with PBS and lysed 
directly on culture dish. Both approaches revealed the same changes in the 
content of bFGF proteins in BAMC subjected to various treatments. Cells 
were lysed in 2 ml of ice cold lysis buffer containimg 1% NP-40, 0.5% deoxy- 
cholate, 20 mM Tris (pH 7.5), 5 mM EDTA, 2 mM EGTA, 150 mM NaCI, 
and protease inhibitors: 0.01 mM PMSF,  10 ng/ml aprotinin,  10 ng/mi 
leupeptin and 10 ng/ml pepstatin. Lysates were clarified by centrifugation 
at 20,000 g  for 15 rain at 4°C,  frozen in liquid nitrogen, and stored at 
-800C. Centrifugation of lysates yielded a small amount of insoluble mate- 
rial. Protein concentrations in supernatants were determined using Bio-Rad 
protein assay (Bio-Rad Laboratories, Richmond, VA).  Supernatants from 
different culture dishes, after minor volume adjustments to provide equal 
amounts of total proteins (0.5-1.5  mg),  were incubated with prewashed 
heparin sepharose for 2 h at 4°C. After washing three times with 20 raM 
Tris HC1 buffer containing 1.0 M NaC1, heparin sepbarose-bound proteins 
were eluted directly into SDS-sample buffer, boiled, and then applied to a 
12 % SDS-polyacrylamide slab gel with a 3 % stacking gel (Florkiewicz and 
Sommer, 1989). After electrophoresis  proteins were transferred to nitrocel- 
lulose as described by Florkiewicz and Sommer (1989) and Puchacz et al. 
(1993).  Membranes were blocked in buffer containing 5% powdered milk 
and incubated with guinea pig anti-18-kD bFGF antisera diluted  1:500 
(Florkiewicz and  Sommer,  1989),  or with bFGF monoclonal antibody 
(Transduction Laboratories, Lexington, KY) followed by rabbit anti-mouse 
IgG. Immune complexes were stained by incubation with 125I-labeled pro- 
tein A. Apparent molecular sizes of bFGF isoforms were determined by 
comparison to concurrently run protein weight standards. As additional 
controls, in some experiments extracts of: (a) COS cells transfected with 
plasmids expressing 18-kD bFGF; or (b) human glioma cells expressing 18, 
22 and 24 kDa bFGF proteins were included. In some experiments media 
combined from two dishes (5  x  107 cells) were processed and analyzed in 
a way similar to the cell extracts to determine whether bFGF was present 
in the media conditioned by BAMC. The levels of individual bFGF isoforms 
were estimated by densitometric scanning of autoradiograms using Beck- 
man DU70 spectrophotometer. Autoradiograms were exposed for different 
length of time to ensure that the signals were in the linear range. 
Analysis of bFGF in Nuclear 
and Cytoplasmic Fractions 
Isotonic lysis of cells and isolation of nuclei and cytoplasmic fraction were 
performed as described by Boyle et al.  (1985)  with minor modifications. 
Cells were incubated in isotonic nuclear buffer containing 0.1% digitonin, 
5 mM sodium phosphate, pH 7.4,  50 mM NaCI,  150 mM sucrose, 5 mM 
KC1, 2 mM dithiothreitol, 1 mM MgCI2,  0.5 mM CaCI2, 0.1 mM PMSE 
10 #M leupeptin, 1 #g/ml aprotinin, 25/~g/mi soybean trypsin inhibitor, 
and 5  ~,g/mi pepstatin A, and collected by gently rinsing the plate with 
buffer.  Nuclei were collected from lysed cells by centrifuging at 500 g for 
10  min at 4°C.  The postnuclear supernatant was further centrifuged at 
40,000 g for 30 min at 4°C to remove cellular debris (P40), and the new 
supernatant ($40) was reserved for the analysis of cytoplasmic (cytosol + 
solubilized  plasma  membrane)  bFGF.  The  crude  nuclear  pellet  was 
resuspended in nuclear buffer, centrifuged through a cushion of TN buffer 
(2.5 mM Tris HCI, pH 7.4,  10 mM NaCI) containing 30% sucrose at 1,000 
g  for  10  min at  40C,  and  the supernatant  was discarded.  Nuclei  were 
resuspended in 50 #1 of nuclear buffer.  Protein content was determined in 
the aliquots of nuclear and cytoplasmic fractions. All samples were frozen 
in liquid nitrogen and stored at -80°C until use. After thawing, the nuclear 
fraction was extracted with 19 volumes of cell lysis buffer containing 1% 
NP-40,  0.5%  deoxycholate.  Lysates were clarified by  centrifugation at 
20,000 g for 15 rain at 4°C. Nuclear or cytoplasmic extracts from different 
cell preparations, after small adjustments to yield the same amounts of pro- 
teins, were purified on heparin sepharose, and subjected to Western analysis 
for bFGF as described below. 
Immunohistochemical Staining for bFGF 
BAMC were plated in eight-chamber slides (Lab-Tek,  Naperville, IL). Af- 
ter treatment, the cells were washed with ice-cold PBS and fixed with 2.6% 
paraformaldehyde in PBS. After washing in PBS with 10 mM glycine, cells 
were permeabilized for 5 rain with 1% Triton X  100 in PBS and blocked 
in PBS containing 1% bovine serum albumin, 2% goat serum, and 10 mM 
glycine for 30 min. As primary antibody we used either monoclonal bFGF 
antibody (UBI, Lake Placid, NY) or polyclonal bFGF antibodies raised in 
guinea pig against human recombinant bFGF (Florkiewicz and Sommer, 
1989),  or in rabbit against a fusion protein joining the 155 residues of hu- 
man bFGF to the amino terminus of ~-galactosidase (gift from Dr. J. Abra- 
ham, California Biotechnology Inc., Mountain View, CA). Antibodies were 
diluted in blocking buffer and added to cells for 24-48 hr. After washing 
with PBS, cells were incubated either with secondary biotynylated anti- 
body for  12-24  h,  followed by incubation with avidin-biotin peroxidase 
(1:400),  or with horseradish-conjugated secondary antibody. Cells were 
washed in PBS and treated with diaminobenzidine-hydrogen  peroxide solu- 
tion, washed again, and coverslipped. Endogenous peroxidase activity was 
exhausted with 0.1% H202 prior to the incubation with the secondary anti- 
body. The specificity of bFGF immunostaining in BAMC was indicated by 
several observations: (a) staining was not observed when primary bFGF an- 
tibody was omitted or substituted with preimmune serum (Puchacz et al., 
1993);  (b) similar nuclear and cytoplasmic staining was observed using 
different polyclonal  or  monoclonal  antibodies,  and  peroxidase or  im- 
munofluorescent staining (see Figs. 4 and 8); and (c) neutralization of  bFGF 
antibody with an excess of 18-kD bFGF also reduced bFGF staining (not 
shown). Specificity of the primary antibodies used for histochemical analy- 
sis was also ascertained by Western analysis. All bFGF antibodies recog- 
nized the same 18-, 22-, and 24-kD bFGF antigens. 
Immunofluorescent staining of bFGF was performed by incubating per- 
meabilized BAMC with monoclonal antibodies against bFGF. As the sec- 
ondary antibody we used fluorescein-conjugated goat anti-rabbit IgG. 
Plasmid Constructions 
The human bFGF promoter fragment was a  gift from R.  Florkiewicz 
(Whittier Institute, La Jolla, CA) (Shibata et al., 1991). The luciferase ex- 
pression vectors were constructed in our laboratory using the promoter- 
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was  constructed  by  isolating  a  2.1-kb  XhoI/SalI  fragment from pF2.1- 
CAT (Shibata et al.,  1991) and cloning it into the Xhol site of pGL2ba~ic. 
(-I,000/+174)bFGFLuc  was constructed by inserting a  1,174-bp  XhoI/ 
HindlII fragment isolated from pF1.2CAT and inserting it into the HindlII 
site of pGL2basic. (-650/+314)bFGFLuc  was constructed from (-1,800/ 
+314)bFGFLuc by digesting with Nsil and MluI followed by blunt ending 
with T4 polymerase and recircularization and ligation. (-512/+314)bFGF- 
Luc was constructed from (-I,800/+314)bFGFLuc using Bal31 nuclease. 
(-274/+174)bFGFLuc was constructed by digesting (-1,000/+174)bFGF- 
Luc with NheI followed by recircularization and ligation. The ends of all 
deletions were determined by DNA sequencing. RSVbGAL was described 
in Edlund et al.  (1985). 
Transfections and Treatments of  BAMC 
Cells  were  transfected  using  either  calcium  phosphate  precipitation, 
lipofectin, or electroporation.  All transfection methods produced similar 
results indicating that different cell treatments did not influence regulation 
of the transfected bFGFLuc genes. For the calcium phosphate method, cells 
(1  x  106) were treated with 3 /~g/35 mm plate of plasmid/calcium phos- 
phate precipitate for 4-8 h  followed by two washes with PBS. DME/F12 
containing 0.25% BSA was then added, Lipofection was done using 12.5 
/zl of lipofectin (GIBCO BRL, Gaithersburg, MD) per 1  ×  106 cells with 
3 #g of plasmid/35 mm plate (Goc and Stachowiak,  1994). The lipofectin 
was removed 6-8 h later and the cells were refed with DME/F12 with 5% 
FCS. 24 h later the cells were washed and refed with DME/F12 with 0.25% 
BSA. The most reproducible transfections of BAMC were obtained by elec- 
troporation. The electroporation was performed using 150 ~tg of plasmid/l 
x  107 cells in a 0.4-cm-wide cuvette and a Gene Pulser (Bio-Rad Labora- 
tories, Cambridge, MA). An electric pulse of 240 V, using a capacitance 
of 960/~F was applied in the buffer described by Chu et al.  (1988).  The 
electroporated cells were then added to 35 mm plates at a density of 2  × 
106  cells/well.  Cells  were  maintained  for  at  least  24  h  in  serum-free 
DME/F12 with 0.25% BSA prior to treatment with drugs. Concentrations 
of forskolin and PMA were  10 and 0.2 #M, respectively, and the time of 
treatment is given in the text. Luciferase assays were done using a Promega 
luciferase assay system on a scintillation counter set to single photon count- 
ing (Goc and Stachowiak,  1994). Transfection efficiency of different plas- 
mids in the same experiment was normalized by measuring directly the in- 
tracellular content of transfected plasmid DNA. To measure the amount of 
DNA directly, we used a modified procedure (Goc and Stachowiak,  1994) 
of Keller and Alwine (1984). After luciferase assays were performed the re- 
maining cell lysate was diluted to 500 ~1 using sterile water. The extract 
(20-50 td) was denatured using 0.2 N NaOH containing 5 mM EDTA (pH 
8.0),  neutralized with Tris-HC1 (pH 8.0),  and blotted onto a  nylon mem- 
brane using a dot blot manifold. Filters were hybridized to a probe made 
from pGem 7Z(-)  (Promega Biotec)  and exposed for  autoradiography. 
Films were then quantified using a microtiter plate reader at 595 nm. The 
amount of intracellular DNA was determined by comparing to a serial dilu- 
tions of plasmid DNA applied directly to the membrane. In several experi- 
ments that examined the effects of forskolin or PMA on the expression of 
transfected bFGFLuc genes, the results across individual plasmids were 
normalized also by co-transfecting the bFGFLuc plasmid with RSVbGAL 
and measuring/Lgalactosidase and luciferase activities in the same extract. 
Treatment of  BAMC with bFGF Antisense and Sense 
bFGF Oligonucleotides 
Modified (phosphoro-thio-DNA backbone) sense (s-bFGF) and anti-sense 
(as-bFGF) oligonucleotides were custom-synthesized  by Bio-Synthesis Inc. 
(Lewisville,  TX).  Their  sequence was  identical  (s-bFGF;  5'GGG  ACC 
AUG GCA GCC 39 or complementary (as-bFGF; 5'GGC TGC CAT GGT 
CCC 3) to the 5' region of human bFGF mRNA (Abraham, 1986b), includ- 
ing the first methionine codon (underlined). Oligomers were purified by gel 
filtration, ethanol precipitated, lyophilized to dryness, and dissolved in cul- 
ture medium. Cells were incubated with 2.5 #M oligonucleotides for 48 h. 
Statistics 
Analysis of variance (ANOVA) was used to test for overall statistical sig- 
nificance. Comparison between groups with N >  4 was made using Neu- 
man-Keuls post hoc test. Direction effects were inferred based on the rela- 
tion of mean values. 
Results 
Stimulation of  Acetylcholine and Angiotensin H 
Receptors Increases Content of  bFGF Proteins 
To characterize bFGF proteins expressed by cultured BAMC, 
total cell lysates were purified with heparin-sepharose and 
subjected  to  western  analysis  with  bFGF  antibodies  and 
~:SI-protein A.  Polyclonal or monoclonal bFGF antibodies 
gave the same results.  In confirmation of earlier observa- 
tions (Grothe and Unsicker,  1990; Presta and Rifkin,  1991; 
Puchacz et al.,  1993) we detected proteins that migrated as 
three  separate  bands  (see  Figures  1-4).  Their  molecular 
weights (18, 22, and 24 kD) were similar to those of human 
bFGF proteins (Florkiewicz and Sommer,  1989).  Human 
and rat bFGFs are generated from alternate utilization of 
CUG or AUG translation initiation codons (Florkiewicz and 
Sommer,  1989;  Powell and Klagsbrun,  1991).  Isoforms of 
bFGF in bovine adrenal  medullary cells  are  likely to be 
generated through the same mechanisms. In the total cell ly- 
sates the ratios of individual isoforms varied slightly between 
cell preparations, but the 24- and 22-kD isoforms were less 
abundant than the 18-kD bFGF in all of the experiments (Ta- 
ble I). 
Most splanchnic nerve terminals innervating adrenal chro- 
marlin cells contain and release acetylcholine. To determine 
whether stimulation of cholinergic receptors could increase 
bFGF content we incubated BAMC with carbachol. Treat- 
ment with carbachol increased the content of all three bFGF 
isoforms.  These  increases  were  detected  after  6  h  and 
achieved maximal levels (2.6-3.4-fold) after 24 h (Fig. 1 A). 
Carbachol-induced increases in the levels of individual 18-, 
22-, or 24-kD isoforms were similar and were statistically 
significant (Fig.  1, legend). To ascertain whether bFGF in- 
duction  was  mediated  by  cholinergic  receptors,  we  pre- 
treated  cells  with  a  mixture  of nicotinic and  muscarinic 
antagonists.  When added before the carbachol,  D-tubocu- 
rarine, and atropine prevented induction of bFGF proteins, 
while antagonists alone had a small increasing effect on 18- 
kD  bFGF  (Fig.  1  B).  To  determine  which  subtype  of 
cholinergic receptors may induce changes in bFGF content 
we treated cells with specific nicotinic (nicotine) or mus- 
Table L  Relative Abundance of Individual bFGF 
Isoforms in BAMC 
Cell fraction  18 kD  22 kD  24 kD 
(Percent of all isoforms) 
Total  cell  extract  55  +  2  27  5:  2~  18  5:  1~ 
Cytosol  55  +  4  30  +  2¢  15  5:  2~§ 
Nuclei  44  5:4  25  5:  2~  31  5:  4'JI 
Cells were fractionated into cytosolic ($40) and nuclear fractions as described 
in the Materials and Methods. Heparin-sepharose purified  extracts were sub- 
jected to Western analysis using bFGF antibody and 1251-labeled protein A. 
Autoradiograms were  scanned using Beckman 70  spectrophotometer.  The 
abundance of individual  bFGF isoforms was expressed as percent of the total 
bFGF content (18- +  22- +  24-kD isoforms) in each sample. Numbers show 
mean +  SEM from nine or ten culture dishes obtained from four (cell  frac- 
tions) or two separate experiments (total cell extracts)  in which cells were in- 
cubated  in  control  medium.  ANOVA demonstrated an overall  statistically 
significant difference in the relative abundance of individual bFGF isoforms (P 
< 0.005) and significant difference between cell fractions (P < 0.01). Newman- 
Keuls test: * P < 0.05, ~ P <  0.01, different  from 18-kD bFGF; § P <  0.05 
different  from 22-kD bFGF;  II p  <  0.05 different  from 24 kD in cytosol. 
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produced similar increases in bFGF protein content as car- 
bachol indicating that cholinergic stimulation of bFGF ex- 
pression  is  mediated  by  nicotinic  acetylcholine  receptors 
(Fig. 1 C). The magnitude of stimulation (2.3-fold for 24-kD 
bFGF,  3.1-fold  for  22-kD  bFGF  and  3.4-fold  for  18-kD 
bFGF) was essentially the same with 10 or 50/~M nicotine. 
Acetyl-/~-methylcholine bromide also increased the levels of 
bFGF proteins. However, its effects were smaller than the in- 
crease produced by nicotine. 
Cells in the adrenal medulla contain a high density of an- 
giotensin receptors that stimulate expression of genes encod- 
ing transcriptional  factors,  catecholamine synthesizing en- 
zymes, and proenkephalin  (Stachowiak et al.,  1990a,c,d). 
Incubation of BAMC for 24 h  with a  stable  analog of an- 
giotensin U,  100 nM sar~-angiotensin II (st-AII), increased 
bFGF protein levels (Fig. 2). The average increase in 18-kD 
bFGF content (2.3-fold) was greater than the increases in 22- 
or 24-kD  bFGF  (1.4-fold).  The  increases  in  the  levels  of 
bFGF proteins were elicited by low (0.2-2 nM) concentra- 
tions of s~-AII indicating that they were mediated by high- 
affinity angiotensin II receptors  (not shown). 
Expression of bFGF Is Increased by Stimulation of 
Two Major Signaling Pathways- cAMP and Protein 
Kinase C 
Stimulation of acetylcholine receptors in adrenal medullary 
cells  increases  concentrations  of cAMP  and the  activities 
of cAMP-stimulated protein kinase A  (PKA) and calcium/ 
phospholipid-stimulated  protein kinase  C  (PKC)  (Guidotti 
and Costa, 1974; Tuominen et al.,  1992). Stimulation of an- 
giotensin receptors also increases  PKC activity and cAMP 
levels  in  the  adrenal  medullary  cells  (Stachowiak  et  al., 
Figure 1. Cholinergic stimulation  increases  content of bFGF pro- 
teins in adrenal  medullary cells.  BAMC were incubated  with cho- 
linergic agonists  and antagonists  or in control drug-free medium. 
All cells were harvested at the same time.  Total cell extracts  were 
prepared  from  individual  culture  dishes  (3  x  107  of  plated 
cells/dish).  Extracts  containing the same amount of protein were 
purified with heparin sepharose and subjected to Western blot anal- 
ysis as described in the methods.  Autoradiograms (A-C) were pro- 
duced by overnight exposure.  Bars represent  results of densitomet- 
ric scanning of autoradiograms. Media combined from two dishes 
were purified  with heparin-sepharose and were processed similar 
to the cell extracts. The presence ofbFGF proteins was not detected 
in the medium from control cells or cells treated  with nicotine or 
ABMCB even after 1 wk of exposure (not shown).  (A) Cells were 
incubated with 200/zM carbachol for the indicated periods of  time. 
(B) Cells were incubated in control medium or with 200 #M car- 
bachol  for 24 h.  Acetylcholine receptors  antagonists;  d-tubocu- 
ratine (dTC;  100 ttM)  and atropine (ATR; 1.5/zM) were added to 
some dishes 30 min before carbachol. Control cultures were treated 
with d-TC and ATR in the same way. Results of densitometric scan- 
ning are summarized on the bar graph. Bars show means  +  SEM 
from (n) or averages of two similarly  treated culture samples.  The 
analysis  of the  combined results  from experiments  (A) and  (B) 
showed  that the increases  in bFGF content produced by 24 h of 
treatment with carbachol (18kD, 2.4 + 0.1-fold; 22 kD, 2.1 +  0.33- 
fold; 24 kD, 2.2  +  0.3-fold)  were statistically  significant  (18 kD, 
P < 0.001; 22 kD, P < 0.05; and 24 kD, P <  0.01). (C) Cells were 
treated  with  nicotinic  (nicotine,  NIC) or  muscarinic  (acetyl-/~ 
methylcholine bromide,  ABMCB) agonists  for 24 h.  Bars  show 
means -1- SEM from three or averages of two similarly treated cul- 
ture samples. 
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or PMA on bFGF protein levels in bovine adrenal medullary cells. 
Cells were treated for 24 h with 0.2 #M PMA, 5/~M  forskolin 
(FSK), or vehicle (0.007  % DMSO). Other culture dishes were in- 
cubated with NGF (50 ng/ml), sarl-angiotensin II (Ang, 100 nM), 
or without drugs (Ctr). Std, standard,  10 ng of 18-kD human 
recombinant bFGE 
1990c; Boarder et al., 1988). To determine whether the acti- 
vation of cAMP signaling pathway increases the levels of 
bFGF, we treated BAMC with adenylate cyclase-stimulating 
forskolin. In cells treated 24 h with forskolin, the levels of 
all three bFGF proteins increased (Fig. 2).  These changes 
were observed in each of four experiments that used differ- 
ent BAMC preparations. The average forskolin-induced in- 
creases in bFGF proteins levels were 3.9 +  1.2 (24 kD), 3.4 
+  0.7 (22 kD), and 2.3  5: 0.7-fold (18 kD). An experiment 
that examined the time course of forskolin-induced changes 
in bFGF protein levels is shown in Fig. 3 A. The results of 
three independent experiments are summarized in Table II. 
Incubation with forskolin for 3 to 6 h increased bFGF protein 
levels minimally. Incubation for 12 h was required to pro- 
duce  larger  increases.  Maximal  increases  occurred  after 
24 h and were sustained during 40 h of treatment. The in- 
creases in the levels of  high molecular weight bFGF isoforms 
(24 and 22 kD) exceeded the increases in the levels of 18-kD 
bFGF. 
Cholinergic and AII stimulation of PKC activity could be 
mimicked by treating BAMC with phorbol esters (Stacho- 
wiak et al., 1990c).  Incubation of BAMC with PKC-stimu- 
lating phorbol ester PMA produced gradual, time-dependent 
increases in the content of bFGF proteins (Fig. 3 B). Unlike 
forskolin, PMA increased predominantly the content of 18- 
kD bFGF isoform (Figs. 2 and 3 B). Thus, stimulation of 
cAMP and PKC signaling pathways increases cellular con- 
tent of bFGF in BAMC, and these two pathways exert differ- 
ent effects on the expression of individual bFGF isoforms. 
Figure 3.  Time course of forskolin- (A) and PMA- (B) induced 
changes in bFGF protein levels. Adrenal medullary cells were in- 
cubated with 5/zM forskolin (F), 0.2 #M PMA or 0.007% DMSO 
(D) for the indicated periods of time. 
cAMP and PKC Increase Content of bFGF Proteins 
in Different SubceUular Compartments 
To  assess  the  functional significance of the  induction of 
bFGF proteins  we examined their localization in adrenal 
medullary cells. The presence of bFGF proteins was not de- 
tected in the medium conditioned by control BAMC or in 
cells treated with cholinergic agonists (legend to Fig. 1), for- 
skolin or PMA (not shown). In a previous study, we detected 
bFGF-immunoreactivity (bFGF-IR) in both the cytoplasm 
and the nuclei of BAMC (Puchacz et al.,  1993).  To deter- 
mine the subcellular localization of changes in bFGF content 
during stimulation of adenylate cyclase or PKC, BAMC were 
stained with antibodies against bFGF (Fig. 4). Cytoplasmic 
bFGF staining had a granular character, consistent with the 
reported presence of  bFGF in secretory vesicles (Westerman 
et al., 1990). Incubation with PMA (12 h) enhanced intensity 
of  bFGF staining in cytoplasm of  many cells but had no effect 
on nuclear staining. In contrast, treatment with forskolin in- 
creased bFGF-IR in the nuclei of the majority of cells with- 
out increasing cytoplasmic bFGF-IR (Fig.  4 A).  In many 
Table II.  Effect  of Forskolin  on bFGF Content  in BAMC 
3h  6h  12h  24h  40h* 
bFGF 
isoform  D  F  D  F  D  F  D  F  D  F 
(bFGF content  -  percent of DMSO control) 
24 kD  73  151  +  40  103  +  14  155  +  37  117  +  9  279  +  95  91  +  6  386  +  117  92  359 
22  kD  77  115  +  26  113  ±  9  128  ±  33  110  ±  11  265  ±  65  290  ±  20  264  ±  34  32  322 
18  kO  88  131  ±  20  109  +  9  145  ±  3  110  ±  I1  153  ±  17  188  ±  3  145  ±  22  82  170 
(2)  (3)  (3)  (3)  (3)  (3)  (3)  (3)  (3)  (1) 
Cells were treated with 5 #M forskolin (F) or with 0.007%  vehicle DMSO (D) for 3, 6,  12, 24, or 40 h. In two experiments (Figs. 2 and 3) additional control 
groups of nontreated cells were included. The levels of bFGF in those cells were similar to those in DMSO-treated cells. The results are expressed as percent 
of mean bFGF levels in DMSO-treated samples. The levels of bFGF isoforms were estimated by Western analysis (see Fig. 3). Numbers represent results of dan- 
sitometric  scanning of autoradiograms.  Numbers show mean  +  SEM of (N) samples obtained in independent experiments using different BAMC preparations. 
* 40-h treatment with forskolin or DMSO was carded out in a separate experiment.  One-way ANOVA revealed that overall forskolin significantly increased 24- 
and 22-kD bFGF (P =  0.05)  and  18-kD bFGF (P <  0.005)  content. 
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ing was reduced. Similar results were obtained in three inde- 
pendent experiments.  Fig.  4  B  shows  the time course of 
forskolin-induced changes in bFGF-IR. Increases in nuclear 
bFGF-IR were detected in some cells after 1-3 h and reached 
maximum levels at 12 h. In the nucleus, areas with stronger 
bFGF-IR, which may represent bFGF in the nucleoli, were 
found (Fig. 4 B and see Fig.  8). 
We used Western analysis of fractionated cells to deter- 
mine subcellular localization of individual bFGF isoforms 
and to verify changes in bFGF distribution in forskolin- and 
in PMA-treated cells, bFGF proteins were detected both in 
the cytoplasmic ($40) and in the nuclear fractions (Fig. 5). 
The P40 pellet containing cellular debris obtained during 
isolation of the cytoplasmic fraction contained only trace 
amounts of bFGF and was not included in further experi- 
ments. The nuclear and cytoplasmic fractions contained all 
three isoforms of bFGE  The contents  of 18-  and  22-kD 
bFGFs were six- and fourfold higher,  respectively, in the 
cytoplasm than in the nuclei. The content of 24-kD bFGF 
was  similar  in  the  cytoplasm  and  in  the  nuclei.  In  the 
cytoplasm the most abundant was the  18-kD isoform, the 
next was 22 kD, and the least abundant was 24-kD bFGF 
(Fig. 5 and Table I). In the nuclei the most and the least abun- 
dant were the 18- and 22-kD isoforms, respectively. The rel- 
ative abundance of the 24-kD bFGF isoform was twofold 
higher in the nuclear than in the cytoplasmic fraction. 
Fig. 6 shows an autoradiogram of an experiment in which 
BAMC were treated with either 5/zM forskolin or 0.2 #M 
PMA, or they were incubated in control medium containing 
0.007 % DMSO. Quantitative results obtained from densito- 
metric scanning of autoradiograms produced in three inde- 
pendent experiments are summarized in Tables HI and IV. 
Incubation with forskolin increased levels of all three bFGF 
isoforms in the nuclear fraction isolated from BAMC (Fig. 
4 and Table III). The time course of those changes was simi- 
lar to that observed in histochemical experiments (Fig. 4 B). 
An elevation in the nuclear content of 18-, 22-, and 24-kD 
bFGF was observed after 3 h of treatment with forskolin. In- 
cubation for 6 and 12 h produced additional increases. Ini- 
tially, at 3 h, the elevation of bFGF proteins in the nuclei was 
accompanied by a small transient decrease in their cytoplas- 
mic content. Later, at 6 and 12 h the contents of bFGF iso- 
forms in the cytoplasmic fraction returned to control levels. 
Incubation of  BAMC with PMA increased the cytoplasmic 
content of all three isoforms of bFGF (Fig. 6 and Table IV). 
These changes were detectable after 3 h. The nuclear content 
of 24- and 22-kD bFGF proteins was not affected by PMA, 
while small 1.5- and 1.3-fold increases in 18-kD bFGF in the 
nuclear fraction were observed after 6 and 12 h of treatment. 
The results of cell fractionation experiments are consistent 
with the histochemical analyses. They show that increases in 
bFGFs content produced by PKC stimulation occur in the 
cytoplasm, whereas stimulation of adenylate cyclase results 
in accumulation of bFGF proteins in the nuclei. 
Increase in bFGF  Protein Content Reflects Increased 
Expression of the bFGF Gene 
Short-term  (3  h)  treatment with  forskolin caused  no  in- 
crease in the total cellular bFGF content (Table I). At that 
time, the increase in nuclear bFGF content was accompanied 
by a reduction in the cytosolic bFGF levels, suggesting trans- 
location of bFGF from the cytoplasm to the nucleus (Table 
NI).  After longer treatment, bFGF content in cytosol re- 
turned to control levels, and the nuclear content showed fur- 
ther increases (Table 111) in parallel with the total cellular 
content of bFGF (Table I).  To determine whether delayed 
elevation of nuclear bFGF may reflect reduced turnover or 
increased synthesis of bFGF, we examined the effects of cy- 
clobeximide on forskolin-induced increase in bFGF content. 
The concentration of  cycloheximide (20 #M) used effectively 
inhibits synthesis of c-fos (Stachowiak, M. K., unpublished 
observations) and general protein synthesis in BAMC (Kcl- 
her and Pollard,  1985). Incubation with cycloheximide for 
12 h did not reduce bFGF content in the nuclei or in the cyto- 
plasmic fraction (Fig. 7). This demonstrates that bFGF has 
a  low  turnover rate;  therefore, a  reduced metabolism of 
bFGF could not account for the forskolin-induced increase 
in bFGF content.  Cycloheximide prevented the forskolin- 
induced increase in nuclear bFGF content consistent with 
the increase in bFGF synthesis. However, the inhibition of 
forskolin induction of nuclear bFGF by cycloheximide could 
be indirect, resulting from inhibited synthesis of other regu- 
latory proteins. Therefore, to specifically inhibit the synthe- 
sis  of bFGF  protein  we  incubated  BAMC  with  15-mer 
antisense (as-bFGF) or sense bFGF (control; s-bFGF) oligo- 
nucleotides. This as-bFGF was shown to inhibit expression 
of bFGF in other cell types (Morrison, 1991). The effects of 
using as-bFGF were similar to those of cycloheximide. A 2-d 
incubation with as-bFGF had little or no reducing effect on 
basal bFGF content, but it prevented an increase in nuclear 
bFGF content by forskolin (Fig. 8). Together these results 
suggest  that  the  induction  of bFGF  protein by  forskolin 
reflects increased synthesis of bFGF rather than decreased 
turnover. 
To determine whether  the  induction  of bFGF  proteins 
reflects increased expression of the bFGF gene, we analyzed 
the abundance of bFGF mRNA.  Bovine bFGF eDNA hy- 
bridized predominantly to RNAs that migrated as a 7-kb and 
a smaller 4.6-kb bands (Fig. 9). Their size was similar to the 
molecular size of bFGF mRNAs found in other cells and 
thought to be generated through the use of different polyade- 
nylation sites (Abraham et al.,  1986a,b; Kurokawa et al., 
1987).  Smaller RNAs that could represent 1.8-2.6-kb an- 
tisense bFGF RNA transcribed from the opposite strand of 
bFGF gene (Zuniga et al., 1993) were not detected. Incuba- 
tion of BAMC with carbachol increased the levels of 7-kb 
bFGF mRNA, and, to smaller extent, that of 4.6-kb mRNA 
(Fig.  9 A).  These changes were observed after  1.5  h  and 
reached a maximum after 6 h. The level of the 7-kb bFGF 
mRNA was also increased by forskolin (Fig. 9, B and C) and 
by PMA (Fig. 9  C).  Changes induced by PMA (Fig, 9 B) 
or by forskolin (not shown) were detected after 1.5 h, like 
the changes produced by carbachol.  They were sustained 
during a continuous 24-h treatment. The effects of PMA and 
forskolin on bFGF mRNA levels were synergistic suggest- 
ing activation through different but interacting mechanisms 
(Fig. 9  C). 
In addition to trans-synaptic and hormonal factors, adre- 
nal medullary cells are also regulated by various growth fac- 
tors. Weich et al. (1991) reported that bFGF stimulates ex- 
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PMA 
FORSKOLIN Stachowiak et al. Regulation ofbFGF Expression  211 Figure 4. Immuno-histochemical localization of bFGF in BAMC. Cells were stained with polyclonal bFGF (A and B) or monoclonal (C) 
bFGF antibodies  as described in the methods.  (A) Effect of forskolin and PMA on subcellular  distribution  of bFGF immtmoreaetivity  in 
adrenal  medullary ceils.  (a) Control; (b) BAMC treated  for 12 h with 0.2 #M PMA; and (c) BAMC treated for 12 h with 5 #M forskolin. 
(B) Time course of  forskolin-induced  changes in bFGF immunostaining in bovine AM cells. 1, Control; 2, cells treated with 0.007% DMSO 
for 24 h; 3, forskolin  1 h; 4, forskolin  3 h; 5, forskolin,  12 h; 6, forskolin  24 h. No difference  in bFGF immunoreactivity was observed 
between DMSO-treated and nontreated ceils.  (C) Localization of bFGF irnmunofluorescenee  in bovine adrenal  medullary cells.  BAMC 
were permeabilized with 1% Triton X-100, and incubated  sequentially  with monoclonal bFGF antibody and fluorescein-conjugated  rabbit 
anti-mouse IgG. 
Figure 5.  bFGF content in nuclear (Nuc) and cytoplasmic (Cyt) 
fractions of  BAMC. Fractions were isolated as described in the text. 
P40 represents  pellet obtained after centrifugation  of postnuclear 
crude cytoplasmic fraction at 40,000 ~ that yielded the $40 cyto- 
plasmic fraction. For direct comparison of bFGF content the entire 
fractions  were  subjected  to  heparin-sepharose  purification  and 
were loaded on gel. (A) BAMC were maintained in control serum- 
free medium. (B) Cells were incubated in control medium with or 
without 10  -9 M  18-kD bFGF. 
pression of its own gene in bovine endothelial cells. We have 
previously reported that the incubation of BAMC with exog- 
enous 18 kD results in a  time-dependent increase in bFGF 
immunoreactivity in the nuclei (Puchacz et al., 1993). To de- 
termine whether this increase could reflect stimulation of the 
synthesis of the endogenous bFGF, we examined the effects 
of bFGF on its own mRNA levels.  Treatment with 0.5 nM 
18-kD bFGF that increased TH and proenkephalin mRNA 
levels in BAMC (Puchacz et al.,  1993) did not induce bFGF 
mRNA (Fig. 9 B). It also failed to enhance the induction of 
bFGF mRNA by forskolin. We analyzed the levels of bFGF 
isoforms in nuclear and in cytoplasmic fractions. Incubation 
with 18-kD bFGF had no effect on the levels of 22- or 24-kD 
bFGF (Fig. 5 B). A dramatic increase in 18-kD bFGF con- 
tent  in  nuclear  and  cytoplasmic  fractions  probably  repre- 
sents accumulation of exogenous  18-kD bFGE 
NGF,  which stimulates  tyrosine kinase activity, also did 
not increase the content of  bFGF proteins in BAMC (Fig. 2). 
Treatment  with  forskolin  and  NGF  produced  similar  in- 
creases as did forskolin alone (Fig.  2). 
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and PMA on subcellular dis- 
tribution of bFGF isoforms in 
BAMC. Cells were incubated 
with 5/~M forskolin, 0.2/~M 
PMA, or 0.007%  DMSO for 
indicated  periods of time. Cel- 
lular  fractions  were  isolated 
and bFGF was analyzed as on 
Fig. 5. 
Transcriptional Activation Is Mediated by the 
Y-flanking Region of the bFGF Gene 
Characterization  and Regulation of the bFGF  Promoter in 
BAMC. Using human genomic clones, Shibata et ai. (1991) 
showed that the bFGF gene contains a  single transcription 
start site and mapped its core promoter to sequences located 
between -480 and +187 (relative to transcription start site). 
To investigate the molecular mechanisms underlying the in- 
duction of bFGF mRNA,  we constructed  a  luciferase re- 
porter plasmid with the promoter sequences isolated from 
the upstream region of the human bFGF gene.  Our initial 
construct,  (-1,000/+174)bFGFLuc  contained  sequences 
from  -1,000  to  +174  bp  (+1  transcription start site).  In 
BAMC transiently transfected with this construct, both for- 
skolin and PMA produced time-dependent increases in lu- 
ciferase expression with  maximal  induction  after  30  h  of 
treatment (Fig. 10). The extent of forskolin and PMA induc- 
tion varied between 2-5-  and  5-20-fold,  respectively, de- 
pending on the preparation of BAMC used. The phorbol es- 
ter  (4-or  phorbol  didecanoate),  which  does  not  stimulate 
PKC,  had  no  effect  on  the  expression of (-1,000/+174)- 
bFGFLuc (not shown).  Treatment of transfected cells with 
both forskolin and PMA produced a  synergistic increase in 
luciferase activity (Fig.  11).  The photon counts obtained in 
cells  transfected  with  the  promoterless  pGI-a~i¢  plasmid 
were similar as the reagent blanks and showed no increases 
in cells treated with PMA or forskolin (Fig.  11,  legend). 
These results indicate that the  -1,000/+174-bp  fragment 
of the bFGF gene  contains the cis-elements  sufficient for 
transcriptional regulation by PMA and cAMP similar to that 
observed in the endogenous bFGF gene. 
Table IlL  Effect of Forskolin  on bFGF Content in Cytosolic and Nuclear Fractions  of BAMC 
3h  6h  12h 
bFGF isoforms  D  F  D  F  D  F 
(bFGF content  -  percent of DMSO control) 
24-kD nuclei  89  +  1  186  +  12  96  +  18  255  +  23  123  a  309  +  10 
Cytoplasm  106  +  8  94  +  14  114  +  8  128  +  27  80  -t- 7  100  +  10 
22-kD nuclei  84  +  8  160  +  17  92  +  3  207  +  13  123  +  6  210  +  26 
Cytoplasm  110  +  8  77  +  3  107  +  9  94  +  1  83  ±  3  90  ±  26 
18-kD nuclei  98  ±  2  183  ±  6  89  ±  6  238  ±  8  114  ±  4  283  ±  22 
Cytoplasm  106  ±  11  79  ±  5  105  ±  13  109  ±  3  89  ±  3  114  ±  23 
Cells were treated with 5/zM forskolin (F) or with 0.007% DMSO (D) as a vehicle for 3, 6, or 12 h. The results are expressed as percent of mean bFGF levels 
in DMSO-treated  samples. Numbers show mean +  SEM of three independent experiments using different BAMC preparations, except a-2 experiments. Forsko- 
lin had an overall statistically significant effect on nuclear content of all three bFGF isoforms (P <  0.001; one-way ANOVA). 
Table IV.  Effect of PMA on bFGF Content in Cytosolic and Nuclear Fractions of BAMC 
3 h  6 h  12 h  24 h 
bFGF isoforms  D  PMA  D  PMA  D  PMA  D  PMA 
(bFGF content  -  percent of DMSO control) 
24-kD nuclei  89  130  74  115  123  91  115  70 
Cytoplasm  106  202  119  292  98  267  76  356 
22-kD nuclei  125  109  68  105  104  96  104  67 
Cytoplasm  104  149  110  183  73  178  115  211 
18-kD nuclei  110  112  90  149  81  133  121  107 
Cytoplasm  82  175  128  205  79  198  117  265 
Cells were treated with 0.2 t~M PMA or with 0.007% DMSO (vehicle) for the indicated period of time. The results represent the average from two culture dishes 
and were combined from three separate  experiments using different  BAMC preparations.  The results are expressed as percent of mean bFGF levels in DMSO- 
treated control samples. 
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tion ofbFGF. Cells were treated for 12 h with 5 ttM forskolin (Fsk), 
0.2 #M PMA, or 0.007% DMSO. Cycloheximide  (Chx) was added 
to dishes 30 min before forskolin  or DMSO and was present in the 
medium for the remainder of the experiment. 
Identification of  Regions of the bFGF Promoter Required 
for cAMP and PKC Regulation.  As shown by our rnRNA 
analysis and transfection experiments, bFGF expression is 
regulated by cAMP and PMA at the transcriptional level. To 
identify the regions of the bFGF promoter that are involved 
in the stimulation of this gene, we conducted a deletion anal- 
ysis of the bFGF promoter (Fig. 11). Deletion of -1,000- to 
-274-bp  promoter  fragment  in  (-1,000/+174)bFGFLuc 
produced a significant (P <  0.0001) decrease in stimulation 
by PMA from 5.9- to 1.8-fold and reduced the basal promoter 
activity (Fig. 11). It also abolished the effect of forskolin and 
reduced  (P <  0.0001) stimulation by combined treatment 
with  forskolin  and  PMA.  This  outcome  indicated  that 
-1,000/-274-bp promoter region supports basal expression 
ofbFGF gene in BAMC and mediates stimulation by forsko- 
lin and PMA. Further deletion analysis was performed using 
(-1,800/+314)bFGFLuc  as the starting construct. It con- 
tains a larger upstream fragment of the bFGF gene (-1,800 
to +314 bp). It produced the same results as those obtained 
for the -1,000/+174-bp fragment (Fig. 11) showing that the 
additional -1,800 to  -1,000 bp are not needed for cAMP 
and PMA  regulation.  Furthermore,  the  sequences  down- 
stream from the transcription start site (+174 to +314 bp), 
coding for the untranslated region of bFGF mRNA, do not 
influence  the  regulation  of  bFGF  promoter  activity  in 
BAMC.  Plasmid (-650/+314)bFGFLuc  showed the same 
stimulation by forskolin, PMA, and by forskolin +  PMA as 
(-1,800/+314)bFGFLuc.  (-650/+314)bFGFLuc  has  de- 
leted an AP-l-like sequence (TTACTCA).  We conclude that 
this sequence does not participate in cAMP or PMA stimu- 
lation of  the bFGF gene promoter in transfected BAMC. The 
next deletion identified a promoter regulatory region located 
between -651 and -512 bp. Deletion of this region signifi- 
cantly inhibited forskolin stimulation (P <  0.0005)  and re- 
duced PMA stimulation (P <  0.0001).  Stimulation by com- 
bined treatment with forskolin and PMA was reduced (P < 
0.001) to the level of PMA alone. This region may also be 
involved in controlling the basal promoter activity since its 
deletion decreased the nonstimulated expression of bFGFLuc 
(Fig.  11). 
In the deletion construct (-274/+174)bFGFLuc, stimula- 
tion by PMA was reduced twofold (P <  0.01) compared to 
(-512/+314)bFGFLuc  indicating that sequences between 
-512  and  -274 also mediated PMA stimulation. (-274/ 
+174)bFGFLuc  still  exhibited  a  residual  stimulation  by 
PMA and by PMA +  forskolin indicating that it contains an 
additional regulatory element(s). 
In conclusion, our deletion analysis indicated the presence 
of multiple regulatory regions in the bFGF gene promoter. 
Region I  (-650  to  -512  bp)  mediated the induction by 
cAMP and PMA and supported basal promoter activity. Two 
other regions were also involved in the stimulation by PKC. 
One of them (region II, -512 to -275 bp) does not contain 
any  known  PMA-responsive  site.  The  other  (region  III, 
-274  to  +174 bp)  contains sequence homologous to the 
AP1 binding site located at -243 to -236 bp within a dyad 
symmetry element. 
Regulation of the bFGF gene by cAMP appeared to be 
mediated by a novel cis/trans mechanism, since we found no 
sequences similar to any known cAMP responsive elements 
(CRE) in the promoter region responsible for cAMP stimu- 
lation. Since induction of many genes by cAMP is mediated 
by the constitutively expressed CREB factor and is not sensi- 
tive to translational inhibitors (Walton and Rehfuss,  1992) 
we examined whether induction of bFGF mRNA is affected 
by cycloheximide. Addition of 20/zM cycloheximide to cul- 
ture medium prior to forskolin prevented induction of bFGF 
mRNA,  suggesting that cAMP stimulates bFGF gene ex- 
pression by acting through inducible or unstable intermedi- 
ate protein(s) (Fig. 12). The induction ofTH mRNA known 
to be mediated by CRE and CREB (Huang et al., 1991) was 
still observed in the presence of cycloheximide. 
Discussion 
Afferent Stimulation Increases Expression  of bFGF in 
AM Cells 
bFGF is a pleiotropic growth factor that has a broader target 
cell specificity than NGF or other known neurotrophic pro- 
teins. Specific effects of  bFGF on cell growth, differentiation 
or survival are the consequence of the time- and location- 
restricted expression of bFGF and bFGF receptors in the 
nervous  system.  Observations  that  the  overexpression  of 
bFGF leads to deregulated growth and neoplastic transfor- 
mation of cells (Couderc et al.,  1991; Quatro et al.,  1991) 
further emphasize the importance of the fine regulation of 
bFGF expression in the nervous system. In contrast to a long 
list of the known effects of bFGF on neuronal, glial, or vas- 
cular cells, little is known about the mechanisms that control 
expression  of bFGF  and  how  it  produces  its  biological 
effects, bFGF is often viewed as a trophic/mitogenic protein 
deposited in extracdlular matrix, that acts in a tonic fashion 
on membrane receptors of the surrounding cells (Baird and 
Walicke,  1989;  Vlodavsky et al.,  1991). The present study 
offers a different view of bFGF as an intracellular cytoplas- 
mic-nuclear protein,  expression of which is  regulated by 
trans-synaptic and hormonal stimuli, and which may serve 
as a direct intracrine mediator of genomic responses to affer- 
ent cell stimulation. 
In this study we show that stimulation of acetylcholine 
receptors increases the content of bFGF proteins in adrenal 
The Journal  of Cell Biology,  Volume 127, 1994  214 Figure 8. Effect of antisense bFGF oligonucleotide on forskolin-induced increase in bFGF protein content. BAMC were incubated for 48 h 
with 2.5/~M sense (s-bFGF)  or antisense (as-bFGF). During last 24 h, cells were treated with 5/xM forskolin or 0.007% DMSO (control). 
Ceils were stained with monoclonal bFGF antibodies as on Fig. 4. 
medullary cells. Nicotine in concentrations that specifically 
activate nicotinic receptors was more potent than the mus- 
carinic  agonist  acetyl-/3  methylcholine  bromide.  Hence 
trans-synaptic induction of bFGF is likely to be mediated by 
a nicotinic subtype of acetylcholine receptors. To the best of 
our knowledge, this is the first demonstration that the activa- 
tion of neurotransmitter receptors increases expression of a 
growth factor protein. Acetylcholine is the main neurotrans- 
mitter and secretagogue released from the splanchnic nerve 
terminals onto adrenal medullary cells and controls the func- 
tions and biology of adrenal medullary cells. Acetylcholine 
and its receptors are also broadly distributed in the central 
and  peripheral  nervous  systems.  Their functions  include 
opening ion channels, changing membrane potential in neu- 
ronal and glial cells, or the stimulating release and synthesis 
of neurotransmitters (Lukas and Bencherif,  1992).  By in- 
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levels  in BAMC.  Total RNA was frac- 
tionated on 1% agarose gel, transferred 
to the nylon membrane and hybridized 
to the bovine bFGF eDNA. Each panel 
shows results  of hybridization (autora- 
diogram) and ethidium bromide stained 
18 and 28 s rRNA. (A) cells were treated 
with  0.4  mM  carbaehol  for indicated 
period of  time. (B) Cells were incubated 
with 5/~M forskolin,  0.5 nM bFGF or 
both for 24 h.  (C)  Cells were treated 
with 0.2 #M PMA or forskolin  or both 
for indicated  periods of time. 
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Figure 10.  Induction of bFGFLuc by forskolin  and PMA.  Cells 
were transfected  with 3/zg of (-1,000/+174)bFGFLue using cal- 
cium phosphate as described in the Materials  and Methods.  Cells 
were first starved for serum for 24 h followed by drug treatment 
at the indicated  times.  Extracts were prepared and protein mea- 
sured.  200--400  #g of protein was used/luciferase assay. 
creasing expression of bFGF, acetylcholine could also regu- 
late cell proliferation and neurite and synapse formation in 
developing and mature nervous tissue. 
Angiotensin  II,  an  effector  peptide  of the  renin-angio- 
tensin system, is another potent activator of adrenal medul- 
lary cells.  Stimulation of AII receptors  induces expression 
of c-fos,  c-jun,  and other related early response genes, fol- 
lowed by transcriptional activation of the TH and PEK genes 
and  increased  synthesis  and  release  of adrenal  medullary 
hormones (for review see Stachowiak and Goc,  1992). The 
present  study  indicates  that the  scope of functions  of AII 
receptors in adrenal medullary cells includes the induction 
of bFGF protein.  AII receptors are found on many periph- 
eral  and  central  neurons  and  glial  cells  (Sumners  et  al., 
1989).  Itoh et al.  (1993) reported recently that angiotensin 
increases synthesis of a bFGF-like factor in smooth muscle 
cells and indicated that this effect is essential for the mitotic 
response to AII stimulation.  Thus, the increase synthesis of 
bFGF may be a general response to angiotensin stimulation, 
common to a  variety of cells. 
The Journal of Cell Biology, Volume 127, 1994  216 Figure 11. Deletion analysis of the bFGF promoter and mapping of the cAMP and PMA-responsive  regions.  BAMC were transfected  using 
DNA lipofection  or electroporation.  (A) Schematic  representation of the different bFGFLuc expression  vectors used in this  study. The 
arrow indicates  the transcriptional  start site of the bFGF gene.  The dashed lines  indicate  the regions of the bFGF promoter implicated 
in cAMP regulation and basal level expression of  the bFGF promoter (I) and in PMA stimulation  (H and III). Also shown are the locations 
of the AP-l-like sites.  The dyad symmetry elements  (DSEs)  shown are potential  regulatory sites discussed in detail in the text.  Plasmid 
construction is described in the Materials  and Methods. (B) Basal promoter activities of individual bFGFLuc plasmids.  Luciferase activity 
was normalized to the amount of plasmid DNA present in transfected  cells.  Results are the mean of six culture dishes  from two different 
cell preparations.  (C) The bar graphs shows levels of induction of luciferase  activity in ceils treated  for 24 hours with forskolin,  PMA, 
or forskolin plus PMA. Luciferase activity in individual  samples was normalized per amount of plasmid  DNA present in transfected  cells 
or per amount of proteins in cell extract used for luciferase  assay. Both methods produced similar  results and data were combined. The 
same results were obtained when luciferase  activity was normalized to B-galactosidase  activity  expressed  from co-transfected  RSVbGAL 
plasmid (not shown).  For each plasmid, luciferase  activity was expressed  relative  to the activity in nonstimulated  cells.  Bars represent 
means  Jr  SEM of (n) culture dishes  in two or three independent  experiments.  ANOVA demonstrated an overall  statistically  significant 
effect of all treatments  (forskolin P < 0.001; PMA P < 0.0001; and Forskolin +  PMA, P < 0.00001) on the expression  of bFGFLuc genes. 
Results of the comparisons between individual  groups using Newman-Keuls post hoc test are discussed in the text.  Luciferase activities 
in promoteriess pGLa~ic plasmid were as follows: Control, 0.213  +  0.14; Forskolin, 0.25  +  0.15; PMA, 0.20 5- 0.07 (n  =  8); Forskolin 
+ PMA, 0.36  +  0.11 cpm/#g protein  x  pg DNA (n  =  6). 
Direct stimulation of adenylate cyclase with forskolin or 
PKC with PMA increased bFGF protein content, indicating 
that cholinergic  and AII stimulations  may be mediated  by 
these two signaling pathways, cAMP and PKC are two sec- 
ond  messengers  that  could  be  accessed  by  a  variety  of 
neurotransmitter  or hormonal  receptors.  Therefore  trans- 
synaptic and hormonal regulation of bFGF expression could 
represent a  general phenomenon of the entire nervous sys- 
tem. Receptors that activate both pathways or the simultane- 
ous activation of cAMP and PKC by different receptors may 
have an enhanced effect on bFGF expression as indicated by 
the synergism between adenylate cyclase and PKC stimula- 
tions. 
bFGF was previously shown to stimulate its own gene ex- 
pression in bovine endothelial cells (Weich et al.,  1991) or 
in human astrocytes (Stachowiak, M. K., Int. Soc. Dev. Neu- 
rosci. Symp.  San Diego, CA, 1994). Although bFGF stimu- 
lated  expression  of c-fos,  c-jun,  TH,  and  proenkephalin 
genes in BAMC (Puchacz et al.,  1993),  it had no effect on 
the expression of the endogenous bFGF gene (Fig. 9 B). Bo- 
vine adrenal medullary cells also contain functional recep- 
tors of NGF (Acheson et al.,  1984).  NGF, however, had no 
effect on bFGF content (Fig.  3).  Therefore,  neither bFGF 
nor NGF is likely to mediate regulation of bFGF gene ex- 
pression in adrenal medullary ceils, and induction of bFGF 
is not a  universal  response to receptor stimulation. 
Increased Expression of the bFGF Gene Underlies 
Induction of bFGF Protein 
The experiments  using cycloheximide and antisense  bFGF 
oligonucleotides indicated that bFGF has a low turnover rate 
and that the induction ofbFGF protein reflects increased syn- 
thesis  of bFGF proteins.  The increased~expression  of the 
bFGF was indicated by the results of our northern analyses. 
Bovine bFGF eDNA hybridized to a  7- and 4.6-kb  bFGF 
mRNAs that may be generated through the use of different 
polyadenylation sites. 
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by forskolin. Cells were incubated for 12 h in control medium or 
with 5 #M forskolin. Cycloheximide  was added to some cultures 
30 min before the start of incubation. The same membrane was hy- 
bridized to bovine TH cDNA, washed, and rehybridized to bFGF 
cDNA. 
In nonstimulated BAMC the levels of "l-kb bFGF mRNA 
were below or close to the detection limit of our assay. This 
suggests  that  either  this  mRNA  is  very  unstable  and  is 
degraded immediately after translation, or that the 4.6-kb 
bFGF mRNA is translated into bFGF proteins in nonstimu- 
lated BAMC. Stimulation of BAMC increased levels of both 
mRNAs indicating that each of them could contribute to the 
induction of bFGF protein. 
Transcriptional  Stimulation of  the bFGF Gene Is 
Mediated through  Unique Regulatory Sequences 
Induction  of bFGF  mRNA  could  reflect  an  increase  in 
mRNA stability as well as increased transcription of the 
bFGF  gene.  Transfection  experiments  using  bFGF  pro- 
rooter-reporter gene constructs demonstrated that changes 
in steady-state levels of bFGF mRNA reflect, at least par- 
tially, increased transcription of bFGF gene and are medi- 
ated through the sequences upstream from its core promoter 
region. Those experiments indicate that sequences between 
-1,000 and +174 bp of the bFGF gene support basal expres- 
sion of bFGF in BAMC and are sufficient for transcriptional 
regulations by cAMP and PKC similar to those observed in 
the endogenous bFGF gene. An additional 800-bp upstream 
or  140-bp  downstream from this region did not influence 
regulation of bFGF promoter activity. Similar to the induc- 
tion of endogenous bFGF mRNA, stimulation of bFGF pro- 
moter activity by cAMP and PKC was synergistic indicating 
participation of separate interacting pathways. Deletion anal- 
ysis revealed that cAMP and PKC stimulations were medi- 
ated partially  through different promoter  regions,  cAMP 
stimulation was mapped to a 138-bp promoter fragment (re- 
gion I) 512-bp upstream from the transcription start site. 
This same region was also found to support basal promoter 
activity in BAMC. The majority of cAMP-inducible genes 
have either CRE (TGACGTCA)  or AP-2 binding elements 
(CCCCAGGC). Only a very small number of genes do not 
belong to these categories (for review see Walton and Reh- 
fuss,  1992).  The  -650/-512-bp  region of the bFGF gene 
shows  no homology to  CRE,  AP-2,  or atypical elements 
conferring cAMP stimulation in the human steroid 21-hydrox- 
ylase (P-450c20 or bovine steroid  17-a-hydroxylase. Com- 
puter analysis of -650/-512 bp of the bFGF gene promoter 
fragment revealed the presence of sequences homologous to 
sites recognized by topoisomerase II and strings of A/T rich 
sequences. Both are characteristic of the matrix attachment 
regions found in other genes (Phi-Van and Strafling, 1990). 
Another interesting feature of this region is the presence of 
three unique dyad symmetry elements (Fig. 7; DSE). These 
types of  elements are known to extrude cruciform-like struc- 
tures using energy derived from negative DNA supercoiling 
(Mizuuchi et al.,  1982) and to bind dimeric transcriptional 
factors (Johnson and McKnight, 1989). 
Induction of  reporter gene by cAMP through CRE or AP-2 
sites is rapid (within 30 min) and insensitive to cyclohexi- 
mide,  a  translational  inhibitor,  indicating recruitment of 
preexisting  transcriptional  factors  (Walton  and  Rehfuss, 
1992). Induction of bFGF mRNA by forskolin was sensitive 
to  cycloheximide suggesting participation of inducible or 
rapidly metabolized intermediary proteins. The induction of 
TH mRNA, which may be mediated by CRE (Huang et al., 
1991), was unaffected by cycloheximide. This suggests that 
different transcription regulatory factors confer cAMP re- 
sponsiveness to bFGF and TH genes in the adrenal medul- 
lary cells.  We propose that the stimulation of bFGF pro- 
moter by cAMP is mediated through cis elements different 
from those currently known and may require novel transcrip- 
tion factors. 
Sequences  that mediate PKC  stimulation were mapped 
within 511  to  -264 bp (region II) of the bFGF gene pro- 
moter. The cAMP-responsive region I (-650 to  -512 bp) 
may also participate in PKC stimulation. These two regions 
do not contain known PMA-responsive elements (AP-1, AP- 
2, NFkB, SRE) found in other genes, suggesting a mecha- 
nism of activation different from those currently known. Re- 
sidual stimulation by PMA of (-274/+174)bFGFLuc (stim- 
ulation was not observed in promoterless pGL2~ic plasmid) 
suggested that region III of bFGF promoter (-274 to +174 
bp) may contain additional PKC-responsive element(s). One 
putative  regulatory  element  may  be  the  TGAGTCA  se- 
quence. It is homologous to the AP-1 binding element found 
in other genes (Angel et al.,  1987),  and it overlaps with a 
20-bp dyad symmetry element. Expression of c-fos, c-jun, 
and related proteins, components of the AP-1 factor is in- 
creased during hormonal or trans-synaptic stimulation of the 
adrenal medullary cells (Stachowiak et al., 1990ad; Goc et 
al., 1992). It is possible that they may play a supporting role 
in the activation of bFGF by PKC in adrenal medullary cells. 
Regulation of bFGF Protein Content 
in Adrenal Medullary Cells Also Involves 
Posttranscriptional  Mechanisms 
Although stimulation of both cholinergic and AII receptors 
increased bFGF protein content, the pattern of changes pro- 
duced by neurotransmitter and hormonal stimulations was 
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similar increases in the levels of all three isoforms whereas 
AII predominantly increased the 18-kD bFGF isoform. Even 
more distinct differences were observed after direct stimula- 
tion of individual second messenger pathways. Stimulation 
of adenylate cyclase predominantly increased 24- and 22-kD 
bFGF levels, whereas activation of PKC increased the con- 
tent of 18-kD bFGF more. A differential regulation of bFGF 
isoforms content has  not been described.  It could reflect 
differential translation of individual bFGF proteins or could 
also be a  result of preferential turnover of individual iso- 
forms. In two experiments we found that cells treated with 
cycloheximide and forskolin had reduced levels of 18-kD 
bFGF compared with cells incubated with  cycloheximide 
alone, while the levels of the 22- and 24-kD bFGFs were less 
affected. Thus, in addition to increasing overall synthesis of 
all bFGF proteins, stimulation of adenylate cyclase could ac- 
celerate the metabolism of 18-kD bFGF leading to a larger 
increase in the content of higher molecular weight bFGF iso- 
forms. 
The biological significance of the presence of different 
bFGF isoforms is still unclear, even though the present study 
shows that their levels could be differentially regulated dur- 
ing cell stimulation and that their subcellular distribution is 
different. Earlier studies by Quatro et al. (1991) and Couderc 
et al. (1991) showed that the over-expression of recombinant 
18-kD bFGF has a different effect on cell growth and tumori- 
genic potential than the overexpression of  the higher molecu- 
lar weight bFGFs.  The effects of differential regulation of 
bFGF  isoforms on  the  biology and  functions  of adrenal 
medullary ceils remains to be determined. 
bFGF May Act as an Intracrine Nuclear Factor in 
Adrenal Medullary Cells 
In this report we established the nuclear and cytoplasmic ex- 
pression of bFGF proteins in BAMC using subcellular frac- 
tionation and western analysis of heparin-sepharose purified 
cytoplasmic and nuclear extracts and immunohistochemical 
techniques for the detection of different epitopes of bFGE 
All three bFGF isoforms were present in the cytoplasmic and 
nuclear fractions, consistent with earlier reports that used 
different cells (Brigstock et al.,  1991;  Florkiewicz et al., 
1991;  Gualandris et al.,  1993).  In the nuclei, levels of all 
three isoforms were similar. In contrast in the cytoplasm, the 
18-kD bFGF was two to fourfold more abundant than the 22- 
and  24-kD  bFGE  The  mechanisms  controlling  nuclear 
translocation of bFGF are still contested. The differential 
compartmentalization  of individual  isoforms  may  be  as- 
sociated with nuclear localization sequences present in the 
amino-terminal extension of  22- and 24-kD bFGFs (Couderc 
et al.,  1991).  Such a  sequence is absent in  18-kD bFGF, 
which translocates to the nucleus less efficiently than the 
higher molecular weight isoforms. Nevertheless, since the 
18-kD bFGF is also found in the nucleus, additional nuclear 
translocation sequence(s) may be present downstream from 
the first AUG codon, or translocation may be mediated in as- 
sociation with a carrier protein. 
In the present study the nuclear staining for bFGF was 
most  striking,  especially  in  cells  treated  with  forskolin. 
Within nuclei,  a  particularly high concentration of bFGF 
was found in the nucleoli. The nuclear presence of  bFGF im- 
munoreactivity'  has also been reported in hippocampal neu- 
rons (Woodward et al.,  1992), in neurons of the trigeminal 
nerve (Matsuda et al.,  1992), in human astrocytes (Stacho- 
wiak,  M.  K., Int. Dev. Neurobiol.  1994.  San Diego, CA, 
1994), and in endothelial cells (Yu et al.,  1993). The cyto- 
plasm of BAMC showed a generalized staining for bFGE 
Darker staining granules were also found suggesting that a 
portion of cytoplasmic bFGF may be associated with vesi- 
cles. The analysis of higher magnification photographs sug- 
gested  apparent  association  of bFGF  with  the  vesicular 
membrane  and  its  absence  inside  vesicles  (Stachowiak, 
M.K.,  unpublished  observations).  Araujo  and  Cotman 
(1992) reported the presence of  a bFGF-like substance in cell 
culture medium of both neuronal or glial cells and its in- 
crease  after treatment  with  growth  factors  or  cytokines. 
Whether this substance, however, represented a partially de- 
graded or intact bFGF protein is unknown. In an attempt to 
determine whether bFGF is released from BAMC, we ana- 
lyzed the culture medium for the presence of bFGF using 
Western blot analysis. No 18-, 22-, or 24-kD bFGF were de- 
tected in the medium conditioned for 24 h by control cells 
or by cells treated with nicotine, PMA, or forskolin. Hence, 
if bFGF is released from BAMC the amount of extracellular 
bFGF must be very small relative to its intracellular content. 
We did not detect bFGF-IR between cultured BAMC that 
might suggest deposition of bFGF in extracellular matrix. 
Increases in bFGF content in BAMC were observed regard- 
less whether cells were lysed directly on the dish or were first 
detached and washed extensively in PBS to remove extracel- 
lular matrix. This indicates that the observed changes reflect 
increases in the intracellular content of bFGE 
As shown for the first time in our studies, the subceUular 
distribution of  bFGF proteins is affected by treatment of ceils 
with agents other than bFGF itself. Angiotensin II or car- 
bachol increased bFGF-IR both in the cytoplasm and in the 
nuclei of BAMC (not shown). Independent stimulation of in- 
dividual receptor signaling pathways revealed that subcellu- 
lar compartmentalization of bFGF is a regulated process. 
Activation  of PKC  increased  the  cytoplasmic content of 
bFGF  proteins,  whereas  stimulation  of adenylate cyclase 
resulted in nuclear accumulation of bFGFs. Association of 
bFGF with secretory granules of BAMC (Westerman et al., 
1990) indicates that bFGF may be released to extraceUular 
medium, interact with plasma membrane, undergo receptor- 
mediated endocytosis, and accumulate in the nuclei.  Our 
earlier observation that bFGF added to culture medium ac- 
cumulated in the nuclei of BAMC suggested such a mecha- 
nism (Puchacz et al., 1993, see also Fig. 5 B). Although we 
cannot rule out this mechanism, our data support nuclear 
translocation independent of release. The absence of intact 
bFGF in culture medium suggests a direct transfer of bFGF 
from the cytoplasm to the nucleus. The initial increase in the 
nuclear content of bFGF in forskolin-treated cells was ac- 
companied by a decrease in cytoplasmic levels of bFGF and 
preceded the increase in the total cell content of bFGE Dur- 
ing this first phase previously synthesized bFGF could be 
translocated from the cytoplasm to the nucleus. The long- 
term accumulation of  bFGF in the nucleus during continuous 
stimulation of adenylate cyclase depended on the synthesis 
of new bFGF molecules. However, an increase in bFGF syn- 
thesis, although necessary, is insufficient for the long-term 
accumulation of nuclear bFGE Stimulation of PKC, which 
also increased expression of the bFGF gene and total bFGF 
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teins.  The  mechanisms that regulate cytoplasmic/nuclear 
distribution of  bFGF proteins could involve posttranslational 
modification of bFGF such as phosphorylation. The rate of 
nuclear  translocation  of  some  transcriptional  factors  is 
stimulated by forskolin and correlates with their increased 
phosphorylation (for review see Whiteside and Goodbourn, 
1993). bFGF contains separate consensus sequences that ac- 
count for its phosphorylation in vitro by cAMP-stimulated 
PKA and by PKC (Feige and Baird, 1989). It is possible that 
nuclear translocation of bFGF in BAMC is caused by its 
phosphorylation with PKA and cytoplasmic accumulation 
by phosphorylation with PKC. However,  whether PKA and 
PKC phosphorylate bFGF in vivo has not been determined; 
hence,  it is  also possible  that the  same results  could be 
achieved by modulating the activities of associated proteins. 
With the observations that bFGFs have no signal sequence, 
remain cell-associated, and may not be secreted by a classi- 
cal mechanism, a regulated targeting of those proteins to the 
nucleus, shown in this study, may be of particular impor- 
tance. Electron microscopic studies of bFGF immunoposi- 
tive neurons showed deposits of  bFGF-IR in euchromatin but 
not in heterochromatin, suggesting that endogenous bFGF is 
conveyed into a transcriptionally active zone of chromatin 
(Matsuda et al.,  1992).  In BAMC bFGF is also associated 
with chromatin and with other nuclear components (Joy, A., 
J.  Shapiro,  and M.  K.  Stachowiak, manuscript in prepa- 
ration). The existence of the mechanism regulating nuclear/ 
cytoplasmic  compartmentalization  of  endogenous  bFGF 
demonstrated in this study suggests that bFGF may play a 
role in the regulation of gene expression by extracellular fac- 
tors. Nakanishi et al. (1992) demonstrated that bFGF affects 
in vitro gene transcription when added to the nuclear extract. 
Bouche et al. (1987) showed that bFGF stimulates activity 
of the RNA polymerase I by acting directly in the nuclei. 
Hence, accumulation of bFGF in the nuclei could have a di- 
rect effect on gene expression and synthesis of ribosomal 
RNA in BAMC. The direct nuclear action of bFGF provides 
a novel mechanism through which peptide growth factors/ 
hormones may regulate gene expression. The existence of 
such a mechanism, in addition to classical signaling systems 
activated by the membrane receptors,  could contribute to 
specificity of transcriptional effects of different factors that 
activate the same second messenger systems. 
bFGF as a Mediator of Cellular Memory 
In the nervous system, information is stored at several differ- 
ent cellular levels (Goelet et al., 1986). Short-term memory 
is generated through covalent modifications of existing mac- 
romolecules that participate in transmission of signals within 
and between neural cells.  The  longer-lasting memory of 
afferent stimulus depends on changes in the synthesis of those 
macromolecules. Permanent memory may involve structural 
remodeling of neural tissue (i.e., alterations in neuritic ar- 
bors, numbers of synaptic contacts, proliferation of neuronal 
and glial cells, and angiogenesis) (Bailey and Kandel, 1993). 
These structural changes require coordinated regulation of 
a great number of genes coding for the functional and struc- 
tural components of the nervous tissue. We have proposed 
that this program of coordinate gene expression is activated 
by the same pleiotropic growth factors that control ontogenic 
development. Our finding that the trans-synaptic and hor- 
monal stimulation of adrenal medullary cells increases ex- 
pression of bFGF is consistent with this proposition. 
Hypothetical Mechanisms of  Functional and 
Structural Adaptations to Afferent Stimulation of 
Adrenal Medulla 
In the adrenal medulla, trans-synaptic or hormonal stimula- 
tion produces an instantaneous release of catecholamines 
and enkephalins from the chromafiin cells. Short-term stim- 
DA  ;p::ri:in~~ LRce~!;  \ 
I  ,YL___Fu_nct_,o    Enk~""  I  ~ps~tvf~rouctural  Adaptati°ns  pi  ~/~  PKA 
~ 
k Angiotensin II 
Ca  ++ 
cAMP  L. ~ | Acetylcholine 
Figure 13. Hypothesis: molec- 
ular mechanisms of  functional 
and structural adaptations to 
stimulation in adrenal medul- 
lary cells. DA, dopamine; NE, 
norepinephrine; E,  epineph- 
fine;  Enk, enkephalins;  P/, 
phosphorylated proteins; SRF 
and CREB, factors binding to 
serum responsive  element and 
CRE, respectively;  PKA, pro- 
tein kinase A; PKC, protein 
kinase C. 
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leading to a transient enhancement in catecholamine produc- 
tion and release.  A  longer or more intense  stimulation of 
chromaflin cells increases  the expression  of TH and pro- 
enkephalin genes resulting in longer-lasting increases in the 
synthesis and release of adrenal medullary hormones. These 
changes occur without apparent proliferation of chromaffin 
cells and are referred to as functional adaptations (Stacho- 
wiak and Goc,  1992; Fig.  13). Long-term afferent stimula- 
tion produces structural changes in adrenal medullary tissue 
that involve  proliferation of chromaflin and other adrenal 
medullary  cells (Tischler and DeLellis,  1988).  Increasing 
the number of cells and total content of adrenal medullary 
hormones may permanently enhance the secretory function 
of the adrenal medulla. 
One mechanism for the induction of structural adaptations 
could be the recruitment of the mitogenic,  angiogenic,  and 
neurite  promoting  factor, bFGE  Depending  on  whether 
PKC or cAMP signaling pathways are activated, bFGF pro- 
teins accumulate in the cytoplasm or in the nucleus. Nuclear 
bFGF  proteins  may  interact directly  with chromatin and 
could thereby regulate expression of batteries of genes  en- 
gaged in cell proliferation and other types of structural and 
functional changes.  In addition to intracrine pathways, ex- 
tracellular bFGF may be taken up by the chromaflin cells and 
also accumulate in the nuclei. 
Although TH or proenkephalin genes are activated by the 
same receptors and second messengers,  the nuclear mecha- 
nisms that stimulate the bFGF gene transcription are differ- 
ent. Transcriptional stimulation of the TH gene is conveyed 
by c-fos and c-jun interacting with the AP-1 binding element 
(Stachowiak et al., 1992; Goc et al., 1992; Goc and Stacho- 
wiak, 1994) and by constitutively expressed proteins that in- 
teract with the CRE (Huang et al.,  1991). Similar mecha- 
nisms  appear to mediate stimulation of the proenkephalin 
gene (Sonnenberg et al., 1989). For the bFGF gene, stimula- 
tion is conveyed by unique regulatory regions and may in- 
volve novel transcriptional factors. The existence of separate 
nuclear mechanisms conveying extracellular stimulation to 
bFGF and to neurotransmitter biosynthetic genes could al- 
low independent modulation of their transcriptional activa- 
tion  by  other  factors.  This  in  turn would  allow  adrenal 
medullary tissue to respond in a graded fashion to afferent 
stimulation:  (a)  through increased  synthesis  of  adrenal 
medullary  hormones,  and  (b)  proliferation  of chromatlin 
cells and angiogenesis. 
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